| Literature DB >> 21804939 |
Firdaus Mukhtar1, Tian P S Oei.
Abstract
This paper aimed to review the literature on depression that focused on its assessment and treatment in Malaysia. PsycINFO, Medline, local journals were searched, and 18 published articles were included in this paper. Results indicate that research on depression in Malaysia, particularly validation studies and psychotherapy research, was weak and fragmented, with minimal empirical evidence available. Pharmacotherapy still dominated the treatment for depression, and, in terms of psychotherapy, Cognitive Behavioural Therapy (CBT) was recently practiced, but only a few studies have reported on the treatment efficacy of CBT. Major limitations of studies were noted, and, consequently, the problems that are associated with the implementation and future direction of clinical and research on depression in Malaysia were discussed. In short, the contribution of empirical research on the assessment and treatment for depression remained inconsistent and fragmented and urgently in need of further empirical investigation.Entities:
Year: 2011 PMID: 21804939 PMCID: PMC3143455 DOI: 10.1155/2011/123642
Source DB: PubMed Journal: Depress Res Treat ISSN: 2090-1321
Figure 1Flowchart of searching articles to review.
Studies on the assessment of depression in Malaysia.
| Study | Target group |
| Ethnicity (%) | Gender | Measure | Cronbach's ( | Validity | EFA/CFA |
|---|---|---|---|---|---|---|---|---|
| (1) Quek et al. [ | Urological | 237 | Malays Chinese (majority) Indian | NA | BDI | Internal Rel. (0.56–0.87); test-retest (0.56–0.87) | Discriminant; specificity and sensitivity | NA |
|
| ||||||||
| (2) Azah et al. [ | Primary care | 265 | Malays (100) | Male ( | PHQ-9, HDRS, HADS | Internal Rel. (0.67); test-retest (0.73) | Concurrent; specificity and sensitivity | NA |
|
| ||||||||
| (3) Oei and Mukhtar [ | Students, general community, primary care, and depressed patients | 1050 | Malays (100) | Male ( | ATQ, BDI, DAS | Internal Rel. (0.90) | Concurrent and discriminant; specificity and sensitivity | EFA/CFA |
|
| ||||||||
| (4) Mukhtar and Oei [ | Students, general community, primary care, and depressed patients | 1050 | Malays (100) | Male ( | BDI, ATQ, DAS | Internal Rel. (0.90) | Concurrent and discriminant; specificity and sensitivity | EFA/CFA |
|
| ||||||||
| (5) Ramli et al. | Patients with diabetes | 153 | Malays (12) Chinese (16) Indian (17) | Male (75) Female (78) | DASS-21 | Internal Rel. (0.74–0.79) | Construct | CFA |
|
| ||||||||
| (6) Mukhtar and Oei [ | Students, general community, primary care, and depressed patients ( | 1050 | Malays (100) | Male ( | DAS, BDI, ATQ | Internal Rel. (0.82) | Concurrent and discriminant; specificity and sensitivity | EFA/CFA |
|
| ||||||||
| (7) Ramli et al. | Patients at Infertility Centre | 246 | Malays (230) Chinese (7) Indian (6) Others (3) | Male (123) Female (123) | DASS-21, HADS | Internal Rel. (0.81–0.83); test-retest (0.82–0.84) | Concurrent | NA |
Note: Key to measure: (ATQ): Automatic Thoughts Questionnaire; (BDI): Beck Depression Inventory; (DAS): Dysfunctional Attitude Scale; (DASS-21): Depression Anxiety Stress Scale-21; (HARS): Hamilton Anxiety Rating Scale; (HDRS): Hamilton Depression Rating Scale; Hospital Anxiety and Depression Scale; (PHQ-9): Malay Version of Brief Patient Health Questionnaire; n = No. of subjects.
Studies on the treatment of depression in Malaysia.
| Study | Disorder or problem | Ethnicity ( | Gender ( | Design | Intervention | Duration of treatment | Outcome measure | Treatment result (+ve/−ve) |
|---|---|---|---|---|---|---|---|---|
| (8) Woon and Teoh [ | Depression with hysterical personality disorder | Chinese ( | Female ( | Case study | Psychodynamic therapy and amitriptyline | 1 year and 5 months | NA | Positive |
|
| ||||||||
| (9) Ong and Lee [ | Depressive neurosis and manic depressive | Malay ( | Male ( | RCT | Nomifensine and amitriptyline | 9 weeks | HDRS; Global clinical parameter | Positive with few adverse effects |
|
| ||||||||
| (10) Indran [ | Depression (12) Dysthymia (3) Anxiety (3) Bipolar (1) Schizophrenia (1) (Outpatient) | Malays ( | Male ( | RCT | Moclobemide | 6 weeks | HDRS; CGI; PGI | Positive with few adverse effects |
|
| ||||||||
| (11) Azhar and Varma [ | Depression | Malays ( | NA | RCT | Religious psychotherapy+ supportive therapy | 15–20 sessions | HDRS | Positive |
|
| ||||||||
| (12) Razali [ | Depression | Malay ( | Male ( | Case study | Dothiepin and maprotiline | 3 month and 1 month | NA | Positive |
|
| ||||||||
| (13) Razali et al. [ | Depression ( | Malays ( | NA | RCT | Religious psychotherapy+ supportive therapy + benzodiazepines or antidepressants | 26 weeks | HARS; HDRS | Positive |
|
| ||||||||
| (14) Razali and Hasanah [ | Depression (Outpatient) | Malay ( | NA | RCT | Amitriptyline, imipramine, dothiepin and maprotiline | 8 weeks | HDRS | Positive |
|
| ||||||||
| (15) Razali [ | Masked Depression (Outpatient) | Malay ( | Female ( | Case Study | Dothiepin | 6 weeks | NA | Positive |
|
| ||||||||
| (16) Ng and Stevens [ | Depression | Malaysian Chinese ( | Male ( | RCT | Sertraline (SSRI) | 6 weeks | HDRS; CGI; LUNSERS; Plasma measurement | Positive with few adverse effects |
|
| ||||||||
| (17) Azhar et al. | Depression (Outpatient) |
| NA | RCT | CBT + ESCCBT + STRCBT + FXT | 12 weeks | HADS; BDI; WHO-QOL | Positive; CBT + ESC show better |
|
| ||||||||
| (18) Mukhtar et al. [ | Depression (Outpatient) | Malays ( | Male ( | RCT | GCBT + TAUTAU | 8 sessions; 1 month | ATQ; DAS | Positive and maintained at 3 and 6 month followups |
Note: KEY to intervention (alphabetical order): Group Cognitive Behaviour Therapy (GCBT); Selective Serotonin Reuptake Inhibitor (SSRI); Escitalopram (ESC); Sertraline (STR); Fluoxetine (FXT); Treatment-as-Usual (TAU)Note: KEY to measures (alphabetical order): Automatic Thoughts Questionnaire (ATQ); Beck Depression Inventory (BDI); Clinical Global Impression (CGI); Dysfunctional Attitude Scale (DAS); Hamilton Anxiety Rating Scale (HARS); Hamilton Depression Rating Scale (HDRS); Liverpool University Neuroleptic Side-effect Rating Scale (LUNSERS); Patients Global Improvement (PGI).